Danaher Corporation (DHR) shares plummeted 6.63% in pre-market trading on Wednesday, January 29th, following the company's fourth-quarter 2024 earnings release.
The key reason behind the stock's sharp decline was Danaher's failure to meet Wall Street's profit expectations for the quarter. The company reported adjusted earnings per share of $2.14, narrowly missing the consensus estimate of $2.16. While revenue of $6.54 billion exceeded expectations of $6.42 billion, the slight earnings miss raised concerns among investors about weak demand from the company's biotech and pharmaceutical clients for its tools and services used in drug development.
Danaher's weaker-than-expected performance in the quarter seems to have caught the market off guard, given the company's strong track record of consistently meeting or exceeding earnings estimates in recent years. The disappointing results have sparked doubts about Danaher's ability to sustain its growth momentum, at least in the near term, as it navigates ongoing challenges in the biotech industry.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。